Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

69.13 +2.52 (+3.78%)
Streaming Delayed Price Updated: 1:44 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tarsus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate in Upcoming Investor Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate in Upcoming Investor Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Announces Proposed $100.0 Million Public Offering
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate in Upcoming Investor Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer
Dr. Yeu transitions from her role as Chief Medical Advisor and Board Member to lead the Company’s newly created Medical Organization 
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.